Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

被引:882
作者
Hylek, Elaine M.
Evans-Molina, Carmella
Shea, Carol
Henault, Lori E.
Regan, Susan
机构
[1] Boston Univ, Sch Med, Boston Med Ctr,Dept Med, Res Unit,Sect Gen Internal Med, Boston, MA 02118 USA
[2] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA
[3] Univ Virginia, Dept Med, Charlottesville, VA USA
关键词
anticoagulants; atrial fibrillation; hemorrhage; stroke;
D O I
10.1161/CIRCULATIONAHA.106.653048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Warfarin is effective in the prevention of stroke in atrial fibrillation but is under used in clinical care. Concerns exist that published rates of hemorrhage may not reflect real-world practice. Few patients >= 80 years of age were enrolled in trials, and studies of prevalent use largely reflect a warfarin-tolerant subset. We sought to define the tolerability of warfarin among an elderly inception cohort with atrial fibrillation. Methods and Results - Consecutive patients who started warfarin were identified from January 2001 to June 2003 and followed for 1 year. Patients had to be >= 65 years of age, have established care at the study institution, and have their warfarin managed on- site. Outcomes included major hemorrhage, time to termination of warfarin, and reason for discontinuation. Of 472 patients, 32% were >= 80 years of age, and 91% had >= 1 stroke risk factor. The cumulative incidence of major hemorrhage for patients >= 80 years of age was 13.1 per 100 person- years and 4.7 for those < 80 years of age (P = 0.009). The first 90 days of warfarin, age >= 80 years, and international normalized ratio (INR) >= 4.0 were associated with increased risk despite trial-level anticoagulation control. Within the first year, 26% of patients >= 80 years of age stopped taking warfarin. Perceived safety issues accounted for 81% of them. Rates of major hemorrhage and warfarin termination were highest among patients with CHADS(2) scores ( an acronym for congestive heart failure, hypertension, age >= 75, diabetes mellitus, and prior stroke or transient ischemic attack) of >= 3. Conclusions - Rates of hemorrhage derived from younger noninception cohorts underestimate the bleeding that occurs in practice. This finding coupled with the short-term tolerability of warfarin likely contributes to its underutilization. Stroke prevention among elderly patients with atrial fibrillation remains a challenging and pressing health concern.
引用
收藏
页码:2689 / 2696
页数:8
相关论文
共 48 条
[1]  
Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
[2]  
Albers GW, 2003, LANCET, V362, P1691
[3]   Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack [J].
Arima, H ;
Hart, RG ;
Colman, S ;
Chalmers, J ;
Anderson, C ;
Rodgers, A ;
Woodward, M ;
MacMahon, S ;
Neal, B .
STROKE, 2005, 36 (10) :2164-2169
[4]   Inflammation as a risk factor for atrial fibrillation [J].
Aviles, RJ ;
Martin, DO ;
Apperson-Hansen, C ;
Houghtaling, PL ;
Rautaharju, P ;
Kronmal, RA ;
Tracy, RP ;
Van Wagoner, DR ;
Psaty, BM ;
Lauer, MS ;
Chung, MK .
CIRCULATION, 2003, 108 (24) :3006-3010
[5]   Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale [J].
Berg, AO ;
Allan, JD ;
Frame, PS ;
Homer, CJ ;
Johnson, MS ;
Klein, JD ;
Lieu, TA ;
Mulrow, CD ;
Orleans, CT ;
Peipert, JF ;
Pender, NJ ;
Siu, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) :157-160
[6]   Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin [J].
Beyth, RJ ;
Quinn, LM ;
Landefeld, CS .
AMERICAN JOURNAL OF MEDICINE, 1998, 105 (02) :91-99
[7]  
Blackshear JL, 1996, LANCET, V348, P633
[8]   Why do patients with atrial fibrillation not receive warfarin? [J].
Bungard, TJ ;
Ghali, WA ;
Teo, KK ;
McAlister, FA ;
Tsuyuki, RT .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :41-46
[9]   Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction [J].
Buresly, K ;
Eisenberg, MJ ;
Zhang, X ;
Pilote, L .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (07) :784-789
[10]   Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].
Connolly, S. ;
Pogue, J. ;
Hart, R. ;
Pfeffer, M. ;
Hohnloser, S. ;
Chrolavicius, S. ;
Yusuf, S. .
LANCET, 2006, 367 (9526) :1903-1912